Search

Objective: Ceftriaxone and metronidazole (CEF/MET) combination therapy is commonly used in the empirical therapy of intra-abdominal infections (IAIs). We aimed to evaluate the treatment response in patients started on empirical CEF/MET therapy and contribute current treatment data on IAIs. Methods: A retrospective analysis was conducted on patients receiving parenteral antibiotic therapy in the general surgery department between 2016 and 2018. Patients aged 18 and older who received CEF/MET therapy for more than 24 hours with a diagnosis of IAI were included. Patient characteristics, antibiotic use and/or surgical history in the last three months, infection source, need for surgical intervention, and clinical and laboratory data were evaluated. Treatment response was analyzed in groups of patients with or without treatment changes. Results: 10,649 patients were evaluated; 591 (5.5%) received CEF/MET therapy, and 297 (50.2%) met the study criteria. Among them, 243 (81.8%) received only CEF/MET treatment (Group 1), while 54(18.2%) received additional antibiotics (median day 5) (Group 2). There was a statistically significant correlation between malignancy, antibiotic use in the last three months and history of surgical intervention and treatment change (p=0.001). The gallbladder (63%) or the biliopancreatic tract (12.1%) were the infection foci in 75.1% of all patients. Treatment was modified in 9.6% of the patients with an infection focused on the gallbladder and 55.6% of the patients with an infection focused on the biliopancreatic tract (p=0.001). Patients with treatment modification had more extended hospital stays and higher mortality rates (p=0.001). Conclusion: Empirical CEF/MET initiation is appropriate for IAIs with a gallbladder focus, yielding a favourable response in four out of five patients. However, CEF/MET therapy may be insufficient in patients with a biliopancreatic tract focus, a history of antibiotic use, malignancy, or surgical intervention, despite source control. Therefore, learning the source of infection and patient characteristics will contribute to the determination of the antibiotic to be selected in empirical treatment, increase treatment success, shorten the hospitalization period, and reduce mortality. [ABSTRACT FROM AUTHOR]

Objective: The study aimed to evaluate the clinical effects of levofloxacin (LEVO) and moxifloxacin (MOXI) prophylaxis during the treatment of acute myeloid leukemia (AML). Methods: This study had a prospective observational design and included AML patients who were scheduled for standard remission-induction (RI) or consolidation (C) chemotherapy. Prophylactic LEVO or MOXI was started at a ratio of 1:1 when neutropenia developed, and two groups were created. The primary endpoint was the frequency of febrile neutropenia (FN) and the time to FN. Results: 120 patients (60 patients in each group) were enrolled in the study. The frequency of FN tended to be higher in the LEVO group but was statistically insignificant (82.1% vs. 75.5%; p=0.702). The time to FN was 10.8±5.7 days and 10.1±5.7 days in the LEVO and MOXI groups, respectively (p=0.393). Microorganisms were izolated in 50.8% of patients who developed FN. The documented infection and bacteremia rate tended to be higher in the MOXI group (71.1% vs. 56.6%; p=0.331 and 87.5% vs. 80.5%; p=0.906). The rates of quinolone resistance were 69.2% and 75% in the LEVO and MOXI groups, respectively (p=0.451). The frequency of FN was higher during the RI phase than the C phase (89.1% vs. 70%; p=0.010). The frequency of documented infection was higher during the C phase than during the RI phase (77.1% vs. 49.1%; p=0.008). Conclusion: This study showed that prophylactic MOXI and LEVO have similar efficacy in AML patients. [ABSTRACT FROM AUTHOR]

Objective: There is not a definitive virological treatment for chronic hepatitis B . Withdrawal of nucleos(t)ide analogue (NA) therapy frequently results in viral recurrence, necessitating lifetime treatment. We aimed to look into the results of discontinuation of nucleos(t)ide analogue therapy in HBeAg negative patients. Methods: Treatment of HBeAg-negative patients without cirrhosis who had suppressed HBV DNA for a mean of ≥7 years and underwent nucleos(t)ide analogue therapy for a mean of ≥7 years were stopped according to the EASL guideline stopping rule. Standard laboratory tests, such as HBV DNA viral load, HBsAg, alanine aminotransferase, and adverse events, were monitored for more than four years during therapy and afterwards. Results: HBsAg loss was not observed in any of the patients during the four-year follow-up period. After the first 12 weeks, HBV-DNA was detected in all patients whose nucleos(t)ide analogue treatment was discontinued. The percentage of patients with HBV DNA >2000 IU/mL was 70% at 6 months, 74% at 12 months, 78% at 24 months, and 79.7% at 36 months, HBV DNA >2000 IU/mL was not detected in remaining patients over a four-year period. In the first year, 26% (n=18) of patients were started treatment for relapse, 46% (n=32) in the second year, 49% (n=34) in the third year, and 55% (n=38) in the fourth year. 45% (n=31) of the patients were still being followed without treatment at the end of the fourth year. Conclusion: Although the follow-up of hepatitis B e antigen-negative CHB patients on NA therapy was longer than in the literature, our recurrence rates were similar to other studies, and no patient lost HBsAg. The most significant benefit was that we were able to follow half of the patients without therapy for more than four years, eliminating the need for the patients to use drugs. [ABSTRACT FROM AUTHOR]

Objective: Urinary tract infections are the most common bacterial infections among community-acquired infections in all age groups. In this study, we aimed to evaluate the distribution of Escherichia coli and Klebsiella spp. in community-acquired urinary tract infections by years and the resistance rates to trimethoprim-sulfamethoxazole (TMP-SXT) and ciprofloxacin antibiotics, which are used as the first choice in community-acquired urinary tract infections. Methods: All urine culture samples from all age groups admitted to the medical microbiology laboratory from outpatient clinics and emergency services between January 2011 and August 2021 were retrospectively analyzed. Samples with E. coli and Klebsiella spp. detected as causative agents in urine cultures were included in the study. Conventional methods and automated systems were used to identify bacteria and for antibiotic susceptibility tests. Results: E. coli (n=50 430) and Klebsiella spp. (n=7763) isolated from urine cultures between January 2011 and August 2021 were evaluated. The lowest and highest resistance rates for ciprofloxacin and TMP-SXT for E. coli were 25-40% and 35-51%, respectively. Ciprofloxacin and TMP-SXT resistance rates for Klebsiella spp. were the lowest and highest at 17-43% and 31-43%, respectively. Conclusion: Knowing the resistance rates of antibiotics used as the first choice against common agents such as E. coli and Klebsiella spp. in treating community-acquired urinary tract infections may guide the empirical antimicrobial therapy. [ABSTRACT FROM AUTHOR]

Objective: The aim of this study, is to investigate the presence of Helicobacter pylori (H. pylori) infection by culture, histology and rapid urease test (RUT) in gastric antrum biopsy samples taken from patients presenting with dyspeptic complaints and to determine the resistance of the isolates to amoxicillin, clarithromycin, levofloxacin and metronidazole by antibiotic gradient method (E-test). Methods: Microbiological and histopathological examinations of 278 biopsy specimens taken from antrum and corpus regions were performed. The presence of H. pylori in biopsy samples was investigated by culture, histology and RUT. Antimicrobial resistance of the isolates against amoxicillin, clarithromycin, levofloxacin and metronidazole was determined by antibiotic gradient method. Sensitivity and specificity of histology and RUT were calculated by accepting culture as the gold standard. Sensitivity and specificity for culture was also calculated by taking the co-positivity of both histology and RUT as the gold standard. Results: H. pylori positivity was detected in 140 of 278 patients with culture, 174 with histology, and 191 with RUT. Sensitivity and specificity of the culture, histology and RUT methods of the patients were 76.5% and 88.3%, 87.8% and 63%, 94.2% and 57.2%, respectively. Antibiotic resistance was investigated by antibiotic gradient method in 140 H. pylori strains isolated from culture. The resistance rates of H. pylori strains to the amoxillin, clarithromycin, levofloxacin and metronidazole were detected as 9 (%6.4), 22 (%15.7), 17 (%12.1), 57 (%40.7), respectively. Conclusions: In the study, RUT was found to be the most sensitive test among culture, histology and RUT methods. Although the specificity of the culture method was high, its sensitivity was found to be quite low compared to other methods. The low sensitivity of H. pylori culture may be caused by factors that affect the chances of direct isolation such as dealing with a fastidious microorganism, clinical sample retrieval and transport conditions. [ABSTRACT FROM AUTHOR]

Objective: Hepatitis B virus is an important health problem leading to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. This study aimed to compare the efficacy and side effects of antiviral drugs used in chronic hepatitis B (CHB). Methods: Five hundred seventy-two patients who were followed and treated with CHB in our clinic were evaluated retrospectively. Results: Fifty-six point five of 572 patients were male, 43.5% were female, and the mean age of the patients was 43.4 ± 12.4. Of the patients, 153 (26.8%) used tenofovir disoproxil fumarate (TDF), 134 (23.4%) telbivudine (LdT), 114 (20%) entecavir (ETC), 92 (16%) lamivudine (LAM), 26 (4.5%) adefovir (ADV), 27 (4.7%) pegylated interpheron alpha (PEG-IFN-α), and 26 (4.6%) used PEG-IFN-α + nucleoside analogue (NA). No significant difference was detected between the treatment groups in terms of age, sex ratio, fibrosis, histological activity index (HAI) score, baseline platelet, international normalized ratio (INR), alpha-fetoprotein (AFP) values (p> 0.05). Seventy (12.3%) of 568 patients were HBeAg (+), 498 (87.7%) were HBeAg (-). At the end of the first year, the virological response rates were 92.5% in LdT, 82.6% in LAM, 72.8% in ETV, 60.7% in TDF, 26.9% in ADV, 22.2% in PEG-IFN-α, 65.3% in PEG-IFN- α+NA groups. Twenty-three point eight of the patients had treatment changes, and 76.3% of these patients preferred TDF as a new treatment. Virological breakthrough was observed at 43.5% in LAM, 13.4% in LdT, 7% in ETV and 0.6% in TDF groups. At the end of 3, 4, and 5 years without treatment change, all patients who continued TDF, ETV, LdT, ADV, and LAM treatment were HBV DNA negative. HBsAg clearance developed in 13 (2.3%) patients. At least one side effect was observed in 169 (29.5%) of all patients, and the group with the most frequent side effects was PEGIFN- α+NA (92.3%) and PEG-IFN-α (77.8%). Amylase increase in LAM (%3.2), CPK increase in LdT (%27.6), CPK increase in TDF (%3.2) groups were the most common side effects. Conclusions: The drug with the lowest virological response rate and the most common side effect is PEG-IFN-α, so its use should be limited to selected patient groups. Treatments with the lowest incidence of side effects and development of resistance were found to be with TDF and ETV. Considering the high virological response rates, TDF and ETV should be preferred in the treatment of CHB. When all treatments are evaluated, HBsAg loss and cure rates are inadequate. [ABSTRACT FROM AUTHOR]

Objective: Skull base osteomyelitis (SBO) is a rare, life-threatening infection and frequently followed and treated by otolaryngologists previously. In this study, we analyzed the diagnosis, treatment and long-term outcomes of SBO from the perspective of infectious diseases and clinical microbiology (IDCM). Methods: Hospitalized patients with SBO between 2012-2019 were evaluated retrospectively. Epidemiological, clinical, laboratory data of the patients were recorded. The patients who recovered with and without sequelae were compared. Results: The mean age of 16 SBO cases was 66 years, 75% of them were male and 87.5% had diabetes mellitus (DM). Cranial nerve and vascular/dural involvement were present in 75% and 56.3% of them, respectively. The most common isolated microorganism were P. aeruginosa, staphylococci and Candida spp. 81.2%, 43.7%, and 56% of the patients received anti-pseudomonal antibiotics, additional glycopeptide and additional antifungal drugs, respectively. The sequelae rate was 46.7% in a 24-month follow-up. Hypertension (p=0.041), duration of complaints (p=0.003), bilateral involvement of skull base (p=0.001), vascular thrombosis/inflammation or dural involvement (p=0.007), previous surgical intervention (p=0.041) and elevated ESR at the end of treatment (p=0.014) were defined as risk factors for permanent sequelae. There was no in-hospital mortality. Conclusions: SBO mainly affects older male patients with DM and causes significant sequelae in half of them. In the cases unresponsive to anti-pseudomonal agents, the addition of antifungal therapy empirically may provide a clinical response. Permanent sequelae are more common in cases with delayed diagnosis/treatment, bilateral, vascular or dural involvement, and elevated ESR at the end of treatment. ESR can be used to determine the treatment response and duration. The follow-up and treatment of SBO cases by IDCM with the support of experienced surgeons may contribute to the positive clinical results. [ABSTRACT FROM AUTHOR]

Objective: Carbapenem-resistant Klebsiella pneumoniae (CRKp) is among the leading causes of hospital-acquired infections worldwide and causes serious and life-threatening infections. Treatment options are very limited for blood stream infections (BSIs) and prognosis is poor due to increasing multi-drug resistance. The aim of this study was to assess risk factors for the mortality due to CRKp-BSI. Methods: A retrospective study was conducted in a university hospital from September 2013 to October 2017. Patients (aged >16 years) with CRKp-BSI were included in this study. Data, including demographics, Charlson comorbidity index (CCI), acute physiology and chronic health evaluation II (APACHE II) score on hospitalisation date, minimum inhibitory concentration (MIC) of CRKp, antibiotic treatment and outcome (30-day mortality) data were collected from the electronic medical records and microbiology databases. Results: A total of 82 patients with CRKP-BSIs were analysed. The median age was 54.5 years, and 48 (58.5%) of them were male. The median APACHE II score on hospitalisation was 14 (IQR 6-28) and CCI was 4.0 (IQR 0-12). Forty-six (56.1%) patients had ICU-acquired bacteremia and 36 (43.9%) had central-line associated bacteremia and 25 (30.5%) had primary bacteremia. Fifty (61.0%) patients had combination therapy, colistin/tigecycline (28%) was the most used antibiotic combination. The mortality of all patients was 56.1% (46/82) and 65.2% (30/46) in ICU patients. In univariate analysis, risk factors for the mortality of CRKp-BSI were high CCI, not having clinical response on the fifth day of treatment, high APACHE II score on hospitalisation and infection date and multiple organ dysfunction syndrome. In multivariate analysis, the most significant risk factor for mortality was APACHE II score on infection day (OR: 1.190; 95% CI: 1.088-1.301). Treatment regimens and combination therapy vs. monotherapy were not found to be significantly associated with survival. In addition, MIC values of CRKp were not associated with mortality. Conclusions: Patients with CRKp-BSI had high mortality (56.1%). APACHE II score on infection day was significantly associated with mortality. The outcome was similar between patients receiving combination (54.3%) or monotherapy (45.7%). [ABSTRACT FROM AUTHOR]

Objective: We aimed to evaluate the epidemiological and clinical characteristics, laboratory and imaging findings and outcome of patients with COVID-19 diagnosis who were hospitalized during the first wave of the COVID-19 pandemic. Methods: A total of 124 cases followed with the diagnosis of COVID-19 were evaluated, retrospectively. Patients with SARSCoV- 2 RT-PCR test result positivity in respiratory specimen were accepted as the confirmed cases. Despite of a negative RT-PCR test result, patients having a combination of compatible symptoms and typical findings of viral pneumonia on thorax computed tomography (CT) were accepted as possible cases. Severe illness was defined as SpO2 ≤93% on room air and to need supplemental oxygen support or mechanical ventilation (MV) or extracorporeal membrane oxygenation. Patients achieving clinical improvement were defined by defervescence of fever for 48 hours, improvement of leukopenia and increase in lymphocyte and thrombocyte count, decrease in demand for oxygen support or weaning from MV. Results: The median age of 124 cases was 54 (minimum-maximum 17-98) years and 59.7% of them were male. Among the overall population, 58% had comorbidities. Most frequent was hypertension (33.9%) followed by diabetes mellitus (16.1%) and cardiac disorders (13.7%). Most common clinical complaints were fever 73.4%), cough (70.2%), and shortness of breath (30.7%). SARSCoV- 2 RT-PCR tests of 81 (65.3%) patients were positive. Severe illness was present in 43 (34.6%) patients and 18 of them were followed in the intensive care unit. Patients with severe illness had higher mean ages, more accompanying comorbidities, and prolonged hospitalization compared to the patients with non-severe illness. Among the laboratory findings, leukocytosis was more than leukopenia. In addition to presence of lymphopenia, thrombocytopenia and hypoalbuminemia, increases in levels of creatinine, D-dimer, and acute phase reactants were more prominent in patients with severe illness. Main thorax CT findings were ground glass opacities (93.3%), often bilateral (73%), involving the lower and lower-middle lobes (48.7%) and showing a peripheral distribution (49.6%). No serious side effects developed during the treatment given according to the recommendations of Ministry of Health Guidelines. Overall mortality rate was 3.2%, and 2 (2.2%) patients died were confirmed cases. Conclusions: The sensitivity of available RT-PCR tests is not sufficient for diagnosis and management of COVID-19. Therefore, combining the imaging methods and serum antibody testing are also needed for management of the disease process. [ABSTRACT FROM AUTHOR]

Objective: Colistin is a concentration-dependent antibiotic which belongs to the polymyxin group of cyclic cationic polypeptide antibiotics. Clinical use of colistin varies due to its complex pharmacokinetic and pharmacodynamic features. In this study, we aimed to evaluate the use of colistin in multidrugresistant Gram-negative bacterial infections. Methods: 193 patients aged ≥18 years who were hospitalized from May 2014 to January 2015 and who received colistin were included in the study. Patient's data were retrospectively evaluated. Pathogens, their resistance rates, dose of colistin, its duration and route of administration, its side effects, and clinical and microbiological responses were recorded. Results: Colistin was administered to the patients with confirmed or suspected infections due to multidrug-resistant Gram-negative organisms approximately on the 20th day of hospital admission. Another antimicrobial was used in combination with colistin administered by IV or intrathecal route in all patients and a carbapenem was the drug most used for combination therapy. IV colistin doses varied widely among patients and a loading dose was not administered in 98% of patients. Inhaled and intrathecal treatment doses were administered in accordance with the literature. Intrathecal colistin administration was always with IV colistin, however inhaled colistin was occasionally administered without IV form. When inhaled colistin alone and combined with IV form were compared, no difference was found in cure rates. The most common side effect of colistin was nephrotoxicity in 33 (25.4%) patients and neurotoxicity in 7 (3.6%) patients. Analyses revealed that advanced age was the only factor which affected the development of nephrotoxicity (p<0.001). Colistin treatment was terminated in 19 patients out of 193 due to side effects. Rate of colistin resistance among infectious agents was 4.3%. Colistin resistance developed on the 19.9±9.4 days of treatment. Cure rate in colistin receiving patients was 56% and the most crucial factor determining the mortality was advanced age (63.9±2) (p=0.001). Conclusions: Nephrotoxicity is the most common side effect of colistin which is one of the treatment options for multidrug-resistant Gramnegative bacterial infections. It has been observed that there were different modes of administration in the same hospital regarding the application of colistin, and the loading dose recommended in the drug package and in the literature was not applied in almost all patients. [ABSTRACT FROM AUTHOR]

Objective: In this study, we aimed to investigate the infections and their clinical outcomes in pregnant women who were hospitalized with a diagnosis of any infectious disease. Methods: Distribution of bacterial and viral infections in 60 pregnant women who were hospitalized due to any infectious disease between years 2015 and 2018 during a three-year period were evaluated retrospectively. Results: Urinary tract infections (65%) and gastroenteritis (8.3%) were the most common bacterial infections, and human immunodefficiency virus (HIV) infection and chickenpox were most common viral infections. All patients were followed at the inpatient clinic except two patients who had hospitalized in intensive care unit due to influenza and Listeria meningitis. An HIV-positive pregnant woman received zidovudin intrapartum and was followed up later. All the other infections recovered without complications. Conclusions: Urinary tract infection was the most common infectious disease among pregnant women. The necessity of hospitalization due to community-acquired but avoidable and vaccine-preventable diseases verified that informing pregnant women about the prevention of infections and screening them before pregnancy against vaccine-preventable diseases. [ABSTRACT FROM AUTHOR]

Objective: Approximately 10-16% of patients with hepatitis C virus (HCV) infection develop kidney disease and the prevalence of HCV infection in patients with impaired renal function is higher than the general population. HCV-positive patients undergoing hemodialysis (HD) have a higher mortality rate compared to HCV-negative patients, not only because of liver-related complications, but also because this contributes to atherogenesis and chronic inflammation. The purpose of antiviral treatment in chronic HCV infection is to eliminate HCV RNA, to obtain a sustained virologic response (SVR), i.e. negative HCV RNA at the end of the 3-month treatment, and to prevent liver complications. Introduction of direct-acting antivirals (DAAs), for the treatment of HCV infection has provided over 90% SVR in the general population. In this study, we aimed to evaluate the demographic characteristics, laboratory values and treatment results of HCV-infected hemodialysis patients treated with DAA. Methods: In this retrospective, single-center observational study, patients undergoing HD in Istanbul Training and Research Hospital Hemodialysis Unit were evaluated. Anti-HCV-positive patients with HCV RNA >15 IU/ml were divided into 2 groups as patients receiving and not receiving DAA treatment. Age, gender, duration of hemodialysis, laboratory values and treatment protocols were recorded. Results: Of the 289 patients followed in the HD unit, 11.4% (33/289) were anti-HCV-positive and 63.6% (21/33) were male, with a mean age of 50.87±7.18 years and HD treatment was given for 84.58±43.44 months. Only 13 patients were using DAA among 18 patients with HCV RNA >15 IU/ml. Standard dose of paritaprevir/ritonavir-ombitasvir/dasabuvir (PrOD) therapy was applied as the DAA protocol and ribavirin was added to the treatment protocol in HCV genotype 1a. All patients were found to have SVR. The most common side effects were fatigue and loss of appetite, and none of the patients had any side effects requiring discontinuation of the drug. Four of the five patients who did not receive treatment were foreign nationals and their DAA treatments could not be provided by Social Security Institution. Conclusions: In HD patients, detection of HCV infection after its screening, and started treatment protocols with low side effects and high SVR will provide source control of HCV infection and decrease mortality and morbidity related to this infection. [ABSTRACT FROM AUTHOR]